Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders presents updated information on the chemistry, signaling of newly derived therapeutic nitric oxide donors/inhibitors, and their complexes in liposomes or nanospheres in both pre-clinical and clinical investigations. The book consists of the following: The program and abstracts presented at the Third International Conference in Udine, Italy, September 3-5, 2023; Parts I-V reviews on (I) the general properties of nitric oxide in diseases (II) the role of nitric oxide in cancer (III) nitric oxide and immunity (IV) nitric oxide and aging and (V) nitric oxide and therapeutics. In addition, part VI is an educational review on artificial intelligence and its application in diseases. These updated reviews present many examples of research investigations related to the application of novel therapeutic compounds on nitric oxide and new derivatives, as well as their significant therapeutic activities against various resistant cancers that are unresponsive to current treatments and in different inflammatory diseases. The book is a valuable resource for cancer researchers, oncologists, graduate students, and investigators from medical and biomedical fields who want to learn more about NO and its therapeutic applications in cancer and inflammatory diseases. The book is also highly useful for both clinicians and oncologists as well as pharmaceutical companies involved in the development of new anticancer/anti-inflammatory agents.
Table of Contents
Part I: General introduction 1. Pathogenic and therapeutic management of cardiac surgery-associated acute kidney injury: Role of nitric oxide biological pathways. Part II: Nitric oxide and cancer 2. The emerging role of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in regulating vasculogenic mimicry in cancer Part III: Nitric oxide reactions in the cells and models to check its biological properties 3. Decoding S-nitrosylation: Theoretical aspects and analytical approaches 4. Preclinical Models to Assess the Pharmacological Properties of NO Derivatives Part IV: Nitric Oxide and neurodegeneration 5. NO-mediated neuroinflammatory pathways as treatment targets in neurodegeneration Part V: Nitric oxide and therapeutics 6. Role of Nitric oxide in Gemcitabine resistance in pancreatic cancer cells 7. Exploring the dual role of nitric oxide in glioblastoma: Therapeutic implications 8. Nitric oxide-donating systems and their potential in shaping tumor immunoregulation 9. Control of nitric oxide synthase 2: Role of NRF2-regulated distal enhancer 10. Nitric oxide in tumour biology: From stemness to metabolic reprogramming 11. Impact of nitric oxide on hemeprotein maturation and its relevance to cancer and pulmonary diseases Part VI: Educational session 12. Using AI to discover new cancer therapies: “Artificial intelligence (AI), the ability of machines to learn from new input, is a broad term for a range of computing methods”. AI is changing drug discovery
Authors
Valentina Rapozzi Associate Professor in Biochemistry, University of Udine, Italy.Dr. Rapozzi is Associate Professor in Biochemistry at the Department of Medicine, University of Udine, Italy. She is Founder and Member of International Society for Nitric Oxide and Cancer and frequent speaker at the yearly International Workshops on Nitric Oxide and Cancer. Her research focuses on the molecular mechanisms of tumor response to oxidative stress induced by photodynamic therapy and chemotherapeutic agents. She is Member of Editorial Board for the Journal Critical Reviews TM in Oncogenesis. She published 84 journal articles and 9 book chapters.
Luigi Xodo Full Professor in Biochemistry, University of Udine, Italy.Dr. Luigi Xodo is Full Professor of Biochemistry at the Department of Medicine of the University of Udine, Italy. His work focuses on unraveling the oncogenes involved in carcinogenesis and on the development of new cancer therapies. In particular, Dr. Xodo's work led to the discovery that the KRAS oncogene, a key player in cellular transformation towards malignancy, is intricately regulated by guanine-rich sequences that adopt unique G-quadruplex structures. This discovery paved the way for targeted interventions against KRAS-related cancers. Dr. Xodo developed effective anti-cancer drugs that could inhibit the KRAS oncogene. One notable approach has been the use of cationic porphyrins that specifically target G-quadruplexes in KRAS mRNA and trigger transcript degradation upon photoactivation. In addition, Dr. Xodo's studies contribute to the discovery of a metabolic reprogramming phenomenon in KRAS-related cancers by elucidating how arginine metabolism shifts to promote the production of polyamines, phosphocreatine and nitric oxide. He is the author of 120 publications in high quality peer-reviewed journals. His academic contributions are evidenced by 120 publications in peer-reviewed journals with high-impact factor, underlining his profound impact on the field of biochemistry and oncology.
Benjamin Bonavida Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, USA.Dr. Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
